Dutch consortium investigates biomarker to identify early-stage melanoma at high-risk of recurrence

Today, SkylineDx announced a research collaboration with an academic hospital and a Dutch cancer registry to investigate patients with early-stage melanoma (skin cancer) at high risk of disease-related fatality. Approximately 90% of all melanoma patients are diagnosed with an early-stage melanoma (American Joint Classification on Cancer [AJCC] stage I/II), without any lymph node metastasis or distant metastasis at time of diagnosis. However, 41% of melanoma-related deaths, are these early-stage patients that are anticipated to have a good prognosis at their diagnosis. As current predictors are not sufficient to identify the specific patient group that should be considered high risk for recurrence, the consortium will dedicate their research to find new or additional variables and attempt to develop an accurate biomarker for this specific purpose. With the aim for a non-invasive tool and identification of this high-risk patient at diagnosis, the consortium collaborates to find these variables in the primary tumor (including genes and proteins). The patient will always have their primary tumor removed; therefore, no additional medical intervention is necessary for this research.

Related Keywords

,Distant Metastasis ,Research Collaboration ,Skin Cancer ,Rotterdam ,Netherlands ,Melanoma ,Lymph Node Metastasis ,Diagnosis ,Skylinedx ,ஆராய்ச்சி இணைந்து ,தோல் புற்றுநோய் ,ரோட்டர்டாம் ,நெதர்லாந்து ,மெலனோமா ,நோயறிதல் ,